May 15, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million. NextCell is a cell therapy company with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes, in a clinical phase II.
» Read moreMay 6, 2020
Swiss Nordic Bio 2020 was held on 6 February in Zurich and was a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland. Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Here you will find the film from the event.
» Read moreMarch 27, 2020
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million. The capital raised in the rights issue will primarily be used to increase the market presence and penetration of SciBase in the US market where an FDA approval of Nevisense 3.0 is expected during the second quarter of 2020.
» Read moreFebruary 3, 2020
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.
» Read more